Results 1 to 10 of about 186,005 (96)

Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma

Experimental Hematology & Oncology, 2020
Pancreatic cancer is one of the most common causes of cancer-related deaths worldwide. The two major histological subtypes of pancreatic cancer are pancreatic ductal adenocarcinoma (PDAC), accounting for 90% of all cases, and pancreatic neuroendocrine ...
H. Gao, Wen-quan Wang, Xianjun Yu, Liang Liu   +3 more
semanticscholar   +1 more source

Computed Tomography-Based Radiomics Signature for the Preoperative Differentiation of Pancreatic Adenosquamous Carcinoma From Pancreatic Ductal Adenocarcinoma

Frontiers in Oncology, 2020
Purpose The purpose was to assess the predictive ability of computed tomography (CT)-based radiomics signature in differential diagnosis between pancreatic adenosquamous carcinoma (PASC) and pancreatic ductal adenocarcinoma (PDAC).
S. Ren, R. Zhao, Wenjing Cui, Wenli Qiu, Kai Guo, Yingying Cao, S. Duan, Zhongqiu Wang, Rong Chen   +8 more
semanticscholar   +1 more source

Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy

World Journal of Gastrointestinal Oncology, 2020
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, with an average 5-year survival rate of less than 10%. Unfortunately, the majority of patients have unresectable, locally advanced, or metastatic disease at the time of diagnosis.
P. Sarantis, E. Koustas, A. Papadimitropoulou, A. Papavassiliou, M. Karamouzis   +4 more
semanticscholar   +1 more source

Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas

Journal of Nuclear Medicine, 2020
Visual Abstract Pancreatic ductal carcinoma (PDAC) is a highly lethal cancer, and early detection and accurate staging are critical to prolonging survival.
M. Röhrich, P. Naumann, F. Giesel, P. Choyke, F. Staudinger, A. Wefers, Dawn P. Liew, C. Kratochwil, H. Rathke, J. Liermann, K. Herfarth, D. Jäger, J. Debus, U. Haberkorn, Matthias Lang, S. Koerber   +15 more
semanticscholar   +1 more source

Carcinogenesis of Pancreatic Ductal Adenocarcinoma.

Gastroenterology, 2020
Although the estimated time for development of pancreatic ductal adenocarcinoma (PDA) is more than 20 years, PDAs are usually detected at late, metastatic stages.
P. Storz, H. Crawford
semanticscholar   +1 more source

The differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma: the values of CT imaging features and texture analysis

Cancer Imaging, 2018
BackgroundImaging findings for pancreatic neuroendocrine carcinoma (PNEC) and pancreatic ductal adenocarcinoma (PDAC) often overlap. The aim of this study was to demonstrate the value of computed tomography (CT) imaging features and texture analysis to ...
Chuangen Guo, Xiaoling Zhuge, Qidong Wang, W. Xiao, Zhonglan Wang, Zhongqiu Wang, Zhan Feng, Xiao Chen   +7 more
semanticscholar   +1 more source

Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3

Journal of Immunotherapy for Cancer, 2019
BackgroundPancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with an overall 5-year survival rate of less than 8%. New evidence indicates that PDAC cells release pro-inflammatory metabolites that induce a marked alteration of normal ...
R. Trovato, Alessandra Fiore, S. Sartori, S. Canè, R. Giugno, L. Cascione, S. Paiella, R. Salvia, F. De Sanctis, O. Poffe, C. Anselmi, Francesca Hofer, S. Sartoris, G. Piro, C. Carbone, V. Corbo, R. Lawlor, S. Solito, L. Pinton, S. Mandruzzato, C. Bassi, A. Scarpa, V. Bronte, S. Ugel   +23 more
semanticscholar   +1 more source

Genetic basis of a common tumor origin in the development of pancreatic mixed acinar-neuroendocrine-ductal carcinoma: A case report

Oncology Letters, 2017
Pancreatic cancer is classified as ductal, acinar, neuroendocrine carcinoma or pancreatoblastoma. Ductal and acinar cells derive from exocrine glands and neuroendocrine cells from endocrine glands; however, mixed acinar-neuroendocrine-ductal carcinoma ...
A. Takano, Y. Hirotsu, K. Amemiya, H. Nakagomi, Naoki Oishi, T. Oyama, H. Mochizuki, M. Omata   +7 more
semanticscholar   +1 more source

Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular-fibrosis and tumor progression

Nature Network Boston, 2016
Fibrosis compromises pancreatic ductal carcinoma (PDAC) treatment and contributes to patient mortality, yet antistromal therapies are controversial. We found that human PDACs with impaired epithelial transforming growth factor-β (TGF-β) signaling have ...
Hanane Laklai, Y. Miroshnikova, Michael W. Pickup, E. Collisson, Grace E. Kim, Alexander S Barrett, Ryan C. Hill, J. Lakins, D. Schlaepfer, J. Mouw, Valerie S. LeBleu, Nilotpal Roy, S. Novitskiy, J. Johansen, V. Poli, R. Kalluri, C. Iacobuzio-Donahue, L. Wood, M. Hebrok, K. Hansen, H. Moses, V. Weaver   +21 more
semanticscholar   +1 more source

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.

Gastroenterology, 2018
Pancreatic ductal adenocarcinoma (PDAC) is resistant to T-cell-mediated immunotherapy. We engineered T cells to transiently express a messenger RNA encoding a chimeric antigen receptor (CAR) specific for mesothelin, a protein that is overexpressed by ...
G. Beatty, M. O'Hara, S. Lacey, D. Torigian, Farzana Nazimuddin, Fang Chen, I. Kulikovskaya, M. Soulen, M. McGarvey, A. Nelson, W. Gladney, B. Levine, J. Melenhorst, G. Plesa, C. June   +14 more
semanticscholar   +1 more source